| Similar Articles |
|---|
 |
Nursing
July 2011
Susan Simmons |
Recognizing and Managing Rheumatoid Arthritis Here's what rheumatoid arthritis is, how it's diagnosed and treated, and what you can do to help patients manage the disease.   |
Chemistry World
June 13, 2007
James Mitchell Crow |
Renewed Therapeutic Promise for Arthritis Patients Three new treatments for rheumatoid arthritis, the most common chronic inflammatory joint disease in the industrialized world, offer hope to patients where existing drugs have failed. |
Nurse Practitioner
February 2011
Jennifer M. Belavic |
Annual Drug Update: 2010 in Review In 2010, the FDA approved several new drugs and new indications for use in primary care. From new therapies for adults with rheumatoid arthritis to a combination drug for benign prostatic hyperplasia, NPs need to be aware of the latest medications now available. |
The Motley Fool
June 15, 2010
Luke Timmerman |
Pfizer Dumps Trubion's Lead Rheumatoid Arthritis Drug, Keeps Next-Gen Product Alive Pfizer tells Trubion: "It's not you. It's me. Well, actually it is you -- I've met someone new." |
American Family Physician
September 15, 2005
Rindfleisch & Muller |
Diagnosis and Management of Rheumatoid Arthritis Rheumatoid arthritis is the most common inflammatory arthritis, affecting 0.8 percent of the adult population worldwide. It is a lifelong disease, although patients can go into remission. Physicians must be aware of common comorbidities. |
The Motley Fool
June 17, 2004
Brian Gorman |
Genentech's Unique Drug Genentech and Biogen Idec's Phase II trial demonstrating Rituxan's effectiveness in treating moderate-to-severe rheumatoid arthritis was enshrined in the prestigious pages of the New England Journal of Medicine, adding heft to the study's results. |
The Motley Fool
April 29, 2011
Brian Orelli |
Nice Efficacy, Pfizer, But... Safety data is most important at this point. Nothing can stop Pfizer's oral rheumatoid arthritis treatment tofacitinib. |
The Motley Fool
August 26, 2009
Brian Orelli |
Small Change, Big Impact? A small difference in wording could have a huge effect on sales of Bristol-Myers Squibb's Orencia. |
Pharmaceutical Executive
December 1, 2010
Walter Armstrong |
Multiple Sclerosis: The Advent of the Orals The $8 billion dollar multiple sclerosis market is set to double the number of available treatments in the near future, with a dramatic switch from injectables to oral medications. |
Nursing
February 2010
Daniel A. Hussar |
New Drugs 2010, PART 1 In this article, you'll learn about 16 new drugs. |
Chemistry World
June 11, 2015
Sarah Houlton |
Companies clamour for CAR-T The biopharmaceutical industry is getting excited about chimeric antigen receptor T-cells, or CAR-T cells, designed to harness the cell-killing power of the immune system. |
Nursing
June 2010
Daniel A. Hussar |
New drugs 2010, part 2 In this article, you'll learn about 14 recently marketed new drugs. |
The Motley Fool
July 14, 2011
Brian Orelli |
Good Data, but Lots of Competition Regeneron's sarilumab passes a phase 2b trial. |
The Motley Fool
December 11, 2009
Brian Orelli |
Roche and Biogen's Blockbuster Making Good Progress Roche and Biogen move their potential blockbuster through the clinical trial maze. |
The Motley Fool
October 8, 2010
Brian Orelli |
Pfizer's Rash (of Bad News) Is Over Data from Pfizer's phase 2 trial testing tasocitinib against psoriasis, a painful autoimmune skin disease, looks promising even given its small size. |
The Motley Fool
March 4, 2011
Brian Orelli |
Pfizer's Biggest Shot at Lipitor 2.0 It might need a little help from competitors. |
The Motley Fool
December 14, 2007
Brian Orelli |
An Overnight Three-Bagger It's not often you see stocks triple in one day, but that's what Rigel Pharmaceuticals did. You might be surprised, however, as to why. Investors, take note. |
Managed Care
November 2005
Vogenberg, Liebeskind & Ritter |
Addressing the Hidden Costs of Rheumatoid Arthritis Health plans can work directly with customers to design rheumatoid arthritis management plans that address indirect but substantial costs. |
The Motley Fool
September 6, 2011
Brian Orelli |
Better Late Than Never? Maybe. Can Vertex's rheumatoid arthritis drug, VX-509, succeed this late in the game? |
Managed Care
March 2006 |
HMOs Want Evidence About Arthritis Drugs Long-term research needs to be done on the cost effectiveness of biologics in fighting rheumatoid arthritis before health plans can be convinced that coverage of the new agents will save money in the long run, a recent study suggests. |
Pharmaceutical Executive
December 1, 2010
Walter Armstrong |
Rheumatoid Arthritis: JAKing Down Inflammation In the race to market the first oral drug to compete with high-priced injectables for rheumatoid arthritis, Pfizer's tasocitinib has the home-stretch lead over Rigel, Vertex, and Incyte. |
The Motley Fool
June 5, 2008
Brian Lawler |
Cancer Concerns Fuel FDA Inquiry The agency examines a class of blockbuster drugs for a link to cancer in young patients. |
American Family Physician
October 1, 2000
Kelly W. Jones, Pharm.D. & Supen R. Patel, M.D. |
A Family Physician's Guide to Monitoring Methotrexate Although the drug is usually prescribed by a subspecialist, a family physician may assume responsibility for monitoring methotrexate therapy... |
The Motley Fool
September 8, 2008
Brian Orelli |
Another FDA Safety Warning (Yawn) The FDA warning results from numerous reports of fungal infections in patients taking TNF inhibitors. |
Managed Care
January 2007 |
The Use of Therapeutic Interchange For Biologic Therapies The stated goal of therapeutic interchange is to achieve an improved or neutral outcome with the new agent while reducing overall treatment costs. |
American Family Physician
September 15, 2005 |
Rheumatoid Arthritis: What You Should Know A patient hand out on the condition, its diagnosis and treatment options. |
Managed Care
December 2007 |
Headlines on Deadline ... Health insurance for all is essential, but not enough... An Ohio House bill may require fully-insured health plans to cover treatment and diagnosis for autism... etc. |
